Skip to main content

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

  • Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial
  • The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year
  • The Safety Review Committee approved the advancement of the Acclaim 1 clinical trial to the Phase 2 expansion portion of the trial

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with diabetes and cancer, recently disclosed favorable preliminary clinical data from the Phase 1 portion of its Acclaim-1 clinical trial. During the study, Genprex’s lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities. In addition, the company reported preliminary evidence of efficacy in the phase 1 portion of the study.

“We are encouraged by the favorable safety profile of REQORSA, as well as the preliminary efficacy data we have observed. These data supported the Safety Review Committee’s approval to advance to the Phase 2 expansion portion of the clinical trial which we expect to begin in the third…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.